Study Confirms CAD Technology is Useful in the Identification of Difficult to Detect Breast Cancers
30 Août 2005 - 3:00PM
PR Newswire (US)
-- iCAD Second Look CAD System Used to Generate Study Data --
NASHUA, N.H., Aug. 30 /PRNewswire-FirstCall/ -- iCAD(R), Inc.
(NASDAQ: ICAD), an industry-leading provider of Computer-Aided
Detection (CAD) solutions that enable healthcare professionals to
identify cancer and other life-threatening conditions earlier,
today announced that its Second Look(R) CAD system was used in the
"Evaluation of Breast Cancer with a Computer-Aided Detection System
by Mammographic Appearance and Histopathology" study published in
the September 1, 2005 edition of Cancer, a journal of the American
Cancer Society. Study findings revealed that CAD technology
effectively identified 98% of the microcalcifications, 95% of the
invasive lobular carcinomas, 89% of the mixed
mass/microcalcification lesions and 84% of the masses in 273 women
with confirmed breast cancer. The study, which was based out of the
Department of Radiology at The George Washington University Medical
Center, concluded that CAD -- with an overall sensitivity of 89% --
represents a useful tool for the detection of breast cancer.
According to the study, "On the basis of lesion histopathology, CAD
showed a higher detection rate for DCIS and invasive lobular
carcinomas. This indicates that CAD has an important role in
reducing the occurrence of missed cancers, even with difficult to
detect lesions, such as invasive lobular carcinoma." Dr. Rachel F.
Brem, Director of Breast Imaging at The George Washington
University Medical Center and study principle investigator said,
"This study further demonstrates the potential of CAD for the
improved diagnosis of breast cancer. It is particularly exciting as
it demonstrates the effectiveness of CAD in cancers that are often
difficult to detect mammographically such as invasive lobular
carcinomas." The study was conducted over a four-year span from
three institutions collecting one thousand consecutive
screen-detected, biopsy-proven breast carcinomas. Every third tumor
was selected until 275 consecutive carcinoma tumors were identified
at random for system testing. Due to incomplete tumor data from two
patients, the study was conducted on 273 carcinomas. From a
consecutive series of 494 women with normal screenings, one hundred
fifty-five mammograms were randomly selected for this study. For
the 265 patients with cancer who had age data available, the mean
age was 60.6 years and for the 154 women with normal mammograms
with age data available, the mean age was 58.9. "Realizing the
significant role that medical research plays in our healthcare
system, iCAD applauds the patients and doctors who participate in
such an important process," said W. Scott Parr, President and CEO
at iCAD, Inc. "iCAD was privileged to take part in a study that
further established the benefits of CAD for the early
identification of breast cancer." According to the American Cancer
Society there will be an estimated 211,240 new cases of breast
cancer in 2005. Early detection of breast cancer can save lives and
often permits less costly and less invasive cancer treatment
options than when detected at a later stage. Described by leading
health insurance providers in the United States as a 'standard of
care' in large radiology practices and a 'medically necessary
adjunct to mammography,' CAD continues to receive strong support
from radiologists, the American College of Radiology and patient
advocacy groups worldwide. About iCAD, Inc. iCAD, Inc. is an
industry-leading provider of Computer-Aided Detection (CAD)
solutions that enable healthcare professionals to identify cancer
and other life-threatening conditions earlier by making medical
services more effective, more accessible and more affordable for
patients worldwide. Recipient of Frost & Sullivan's Growth
Strategy Leadership award, iCAD offers a comprehensive range of
high-performance, upgradeable CAD systems for the high, mid and low
volume mammography markets. As the most frequently selected CAD
solution for film-based and digital breast screening, iCAD is
entrusted with the task of early cancer detection by over one
thousand women's healthcare centers worldwide. For more
information, call 877 iCAD now or visit http://www.icadmed.com/.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: Certain statements contained in this News
Release constitute "forward- looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited to, the risks
of uncertainty of patent protection, the impact of supply and
manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence, increased
competition, customer concentration and other risks detailed in the
Company's filings with the Securities and Exchange Commission. The
words "believe," "demonstrate," "intend," "expect," "estimate,"
"anticipate," "likely," and similar expressions identify forward-
looking statements. Readers are cautioned not to place undue
reliance on those forward-looking statements, which speak only as
of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in
this release. iCAD and Second Look are registered trademarks of
iCAD, Inc. For more information on iCAD, Inc., contact Kevin
McGrath of Cameron Associates at 212 245 4577 or via email at . For
all other inquires, contact Monica Pandolfi of SHIFT Communications
at 617 681 1235 or via email at . DATASOURCE: iCAD, Inc. CONTACT:
Kevin McGrath, +1-212-245-4577, , or Monica Pandolfi,
+1-617-681-1235, , both for iCAD, Inc. Web site:
http://www.icadmed.com/
Copyright